Open Access Highly Accessed Case report

Feasibility of combination allogeneic stem cell therapy for spinal cord injury: a case report

Thomas E Ichim1, Fabio Solano2, Fabian Lara2, Eugenia Paris3, Federico Ugalde2, Jorge Paz Rodriguez2, Boris Minev4, Vladimir Bogin15, Famela Ramos1, Erik J Woods6, Michael P Murphy7, Amit N Patel8, Robert J Harman9 and Neil H Riordan1*

Author Affiliations

1 Medistem Inc, San Diego, USA

2 Medistem Panama, City of Knowledge, Clayton, Panama

3 Hospital CIMA, San Jose, Costa Rica

4 University of California, San Diego, California, USA

5 Cromos Pharma, Longview, Washington, USA

6 General Biotechnology, Indianapolis, Indiana, USA

7 Division of Medicine, Indiana University School of Medicine, Indiana, USA

8 Dept of Cardiothoracic Surgery, University of Utah, Salt Lake City, Utah, USA

9 Vet-Stem Inc, Poway, California, USA

For all author emails, please log on.

International Archives of Medicine 2010, 3:30  doi:10.1186/1755-7682-3-30

Published: 11 November 2010


Cellular therapy for spinal cord injury (SCI) is overviewed focusing on bone marrow mononuclear cells, olfactory ensheathing cells, and mesenchymal stem cells. A case is made for the possibility of combining cell types, as well as for allogeneic use. We report the case of 29 year old male who suffered a crush fracture of the L1 vertebral body, lacking lower sensorimotor function, being a score A on the ASIA scale. Stem cell therapy comprised of intrathecal administration of allogeneic umbilical cord blood ex-vivo expanded CD34 and umbilical cord matrix MSC was performed 5 months, 8 months, and 14 months after injury. Cell administration was well tolerated with no adverse effects observed. Neuropathic pain subsided from intermittent 10/10 to once a week 3/10 VAS. Recovery of muscle, bowel and sexual function was noted, along with a decrease in ASIA score to "D". This case supports further investigation into allogeneic-based stem cell therapies for SCI.